XML 27 R16.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has determined that it operates in a single reportable segment, which is the research and development of innovative drug candidates for the treatment of human cancer. Resources are allocated and performance is assessed by the Company's President and Chief Executive Officer, whom the Company has determined to be its Chief Operating Decision Maker (CODM).
The CODM considers actual operating results on an annual basis or as needed on a consolidated basis, including consolidated net loss, when making decisions about allocating capital and personnel to the segment in the annual budgeting and forecasting process, which includes comparison of budget to actual and current period to prior period variances. The CODM assesses performance for the operating segment and decides, in part, how to allocate resources based on net loss that also is reported on the Condensed Consolidated Statement of Operations as net loss. The measure of segment assets is reported on the Condensed Consolidated Balance Sheets as total assets. The Company’s long-lived assets are located in the United States.
In addition to the significant categories included within net loss presented on the Company's Condensed Consolidated Statement of Operations, the following table is representative of the significant expense categories for the three months ended March 31, 2026 and 2025, including a reconciliation to Net loss:
Three Months Ended March 31,
20262025
Revenues, net$— $2,380 
Direct research and development3,652 4,997 
Research and development employee related2,499 3,130 
General and administrative employee related1,767 1,884 
Professional, legal, and consulting2,616 1,263 
Change in fair value of warrant liability12,757 — 
Other segment items (1)
908 1,722 
Net loss$24,199 $10,616 
(1) Other segment items for the three months ended March 31, 2026 include facility related costs, insurance costs, and interest income. Other segment items for the three months ended March 31, 2025 include cost of royalties, facility related costs, insurance costs, expense related to the sale of future royalties, and interest income.